Ino-3107 awarded the innovation passport designation under u.k. government's innovative licensing and access pathway

Award recognizes the potential for ino-3107 to be the first therapeutic option in the united kingdom for patients suffering from recurrent respiratory papillomatosis (rrp) plymouth meeting, pa. , july 11, 2024 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv-related diseases, cancer, and infectious diseases, today announced that its lead dna medicine candidate, ino-3107, has been designated an innovative medicine as part of the u.k.'s innovative licensing and access pathway (ilap).
INO Ratings Summary
INO Quant Ranking